CCM
NRIX icon

CAAS Capital Management’s Nurix Therapeutics NRIX Stock Holding History

CAAS Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-40,000
Closed -$1.4M – 891
2020
Q3 		$1.4M Buy
+40,000
New +$1.01M 0.03% 302

Other funds holding NRIX

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAAS Capital Management's NRIX Position: Q4 2020 in Review

CAAS Capital Management sold out of Nurix Therapeutics (NRIX) in Q4 2020, closing a stake of 40,000 shares — an estimated $1.4M sold.

CAAS Capital Management first reported a position in NRIX in Q3 2020 and held it in 1 quarter. The position peaked at $1.4M in Q3 2020. 68 funds tracked by Wall St. Rank hold NRIX as of Q4 2020.

  • CAAS Capital Management reported no remaining Nurix Therapeutics position as of Q4 2020 after selling out during the quarter.
  • CAAS Capital Management sold 40,000 Nurix Therapeutics shares in Q4 2020, an estimated $1.4M.
  • CAAS Capital Management first reported a position in Nurix Therapeutics in Q3 2020 and held it in 1 quarter.
  • CAAS Capital Management's Nurix Therapeutics position peaked at $1.4M in Q3 2020.
  • 68 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2020.

Based on CAAS Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.